Paediatric Vaccine Market
Market Insights on Paediatric Vaccine covering sales outlook, demand forecast & up-to-date key trends
Paediatric Vaccine Market by Indication, Technology, Vaccine, End User & Region - Forecast 2022 - 2032
Paediatric Vaccine Market Snapshot (2022-2032)
[250 Pages Report] The global paediatric vaccine market is expected to enjoy a valuation of US$ 48.8 Bn by the end of the year 2022, and further expand at a CAGR of 12.7% to reach a valuation of US$ 160.7 Bn by the year 2032. According to the recent study by Future Market Insights, pneumococcal vaccine by indication is leading the market with a share of about 31.9% in the year 2021, within the global market.
Market Outlook:
|
Data Points |
Market Insights |
|
Market Value 2021 |
US$ 44.1 Bn |
|
Market Value 2022 |
US$ 48.8 Bn |
|
Market Value 2032 |
US$ 160.7 Bn |
|
CAGR 2022-2032 |
12.7% |
|
Market Share of Top 5 Countries |
39.8% |
|
Key Market Players |
GlaaxoSmithKline Plc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech and Indian Immnunologicals, Catalent Inc, Robinson Pharma, Inc., Hunan Er-Kang Pharmaceutical Co., Ltd., Procaps, CAPTEK Softgel International Inc., Softcaps, Fuji Capsule Co., Ltd., Aenova Holding GmbH, Sirio Pharma Co., Ltd., Bahrain Pharma, Sinovac Biotech Ltd., and AstraZeneca plc. |
Global demand for paediatric vaccines market is expected to grow due to increasing live births and increasing number of infectious diseases like pneumonia, malaria, diarrhoea, and tuberculosis.
Some major disease like Hepatitis A., Hepatitis B., HPV (human papillomavirus, polio, tetanus, and rubella majorly affect the paediatric population due to their weak immune system. Paediatric vaccines protect children to affect by such disease will further expand the market globally.
Let us know your requirement to get
100% FREE customization
Sales Analysis Of Paediatric Vaccine Market From 2014 To 2021 Vs Market Outlook For 2022 To 2032
The market value for the paediatric vaccine is approximately 31.9% of the overall US$ 138.7 Bn of the global vaccines market in 2021.
The sales of paediatric vaccine expanded at a CAGR of 9.4% from 2014 to 2021, owing to the advent of the COVID-19 global pandemic.
Due to the steadily growing demand, manufacturers in the industry are concentrating more on paediatric vaccines. Globally, numerous infections are transmitted, and children's weak immune system makes them more susceptible to infections. The market for paediatric vaccines is expanding globally as a result of this factor.
There is an increasing development of vaccinations using cutting-edge technology. For instance, Merck reported on the immunogenicity, safety, and tolerability of VAXNEUVANCETM (Pneumococcal 15-valent conjugate vaccine) in healthy new-borns enrolled between 42 and 90 days of age.
Manufacturers of paediatric vaccinations are working to create combination vaccines for diseases like attenuated vaccine and inactivated or killed vaccine. As a result, fewer institutional visits are required, which is intended to promote compliance with the immunisation programme.
Furthermore, players in the market are likely to concentrate their efforts on resolving various supply and production constraints in the vaccine industry to get an advantage in the paediatric vaccine market.
The newly developed COVID-19 vaccinations will likely start to be tested on children by several companies. For Instance, on 24 June 2022, in a report published by the Centers for Disease Control and Prevention, CDC Director suggested Moderna's COVID-19 vaccination be used as an alternative for children aged 6 through 17 years, in addition to its existing recommended usage in children 6 months through 5 years and adults 18 years and older.
What Are The Key Opportunities For The Paediatric Vaccine Market Manufacturers?
The increasing investment of government and non – government organizations in increasing awareness, and favourable reimbursement policies are anticipated to boost the growth of the market.
Furthermore, increased emphasis on immunization programs to build awareness regarding the benefits of vaccination and increasing the accessibility of vaccines by making them available at affordable rates at government institutions will boost market expansion for paediatric vaccines.
Factors such as economic growth in emerging markets, increasing awareness of vaccines and immunization among the population, as parents are now more aware of vaccines and advanced features after use, are set to enhance the sales of the overall market.
Increasing research collaborations for the development of innovative vaccines and management of end users in order to enhance the reach of vaccines are important factors contributing to the growth of the global paediatric vaccine market.
The global paediatric vaccines market is anticipated to experience significant growth over the course of the assessment period as a result of recent developments and breakthroughs in next-generation rotavirus vaccines.
Furthermore, the development of new rotavirus vaccines has been significant in reducing the incidence of hospital admissions for diarrhoea among children five years old or younger. This is a major driving factor to boost the demand for paediatric vaccines.
Additionally, when incorporated into national immunization programs, rotavirus has shown to be a fully effective, long-term, and cost-effective treatment. Hence, demand within the paediatric vaccine market is continuously surging.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat Are The Factors Restraining Demand For Paediatric Vaccines?
The high cost of vaccine refrigeration is anticipated to impede market expansion. Refrigeration is essential for vaccines to prevent mutations in their chemical structure, which are mostly caused by interaction with water and humidity and thus turn into useless drugs. About 80% of the expense of vaccinations goes into maintaining the cold chain from the point of production until the vaccines are administered.
Additionally, it is anticipated that the limited functional shelf life of several vaccines may restrain market expansion.
Lack of accessibility to paediatric medications in emerging nations due to inadequate healthcare infrastructure and less awareness are the factors restricting the market's growth.
Inappropriate or excessive vaccination doses can possibly cause a child's death. This factor will restrain the growth of paediatric vaccines in the forecast period. Additionally, doctors may administer vaccines with an expiration date in rural areas where there is a lack of public understanding regarding paediatric vaccines, which will diminish market demand.
Country-Wise Insights
What Makes the U.S. a Highly Lucrative Market for Paediatric Vaccines?
U.S. holds approximately 72.7% share in the North American market in 2021 and is projected to display growth at a lucrative CAGR of 11.9% during the forecast period.
Over the projection period, North America is anticipated to contribute the largest market share. This can be due to significant R&D expenditures and the general public's high awareness of various medical diseases. In the U.S healthcare facilities are increasing developing, and people are more aware of vaccines and immunization for children.
What Makes the China a Large Market for Paediatric Vaccine?
China holds a market share of around 5.6% in the global market in 2021.
The presence of market players in china is expanding and manufacturers generally focus on vaccines for the paediatric age group since after the COVID-19 outbreak.
For instance, on June 20202, a report published by the National Library of Medicine, Between January 16 and February 8, 2020, the Chinese Centers for Disease Control and Prevention received a nationwide case series of 2135 paediatric patients with COVID-19.
What is the Outlook of U.K. in the Paediatric Vaccine Market?
U.K. holds approximately 24.7% share in the European market in 2021 and is projected to display growth at a lucrative CAGR of 15.3% during the forecast period.
Campaigns to immunise people against infectious and chronic diseases were launched in the UK in the 20th century. The UK Health Security Agency (UK HSA) created a timeline of vaccine development over time as well as the start of routine immunisation programmes in the UK, which is also advantageous for the paediatric population.
The U.K. government took the lead in children's development and introduced a number of programmes for paediatric group immunisation.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-Wise Insights
Which Paediatric Vaccine Indication Is Driving Market Growth?
The pneumococcal vaccine by indication is expected to present a high growth, holding a market share of 31.9% in 2021, and the segment is expected to grow with a CAGR of about 15.0% in the global market during the forecast period.
The pneumococcus bacterium causes the pneumococcal disease. One of the age groups most at risk for the illness is children under 2 years old. Hence, CDC recommended that all children under the age of two should receive the pneumococcal conjugate vaccine on a regular basis.
Which Technology of Paediatric Vaccine is more in Focus Globally?
The conjugate vaccine technology targeted for paediatric vaccine holds the highest market share of 32.0% during the year 2021, with a CAGR of about 13.0% over the forecast years, in the global market.
Conjugate vaccines have been developed for children to trigger a significant immune response against bacterial capsular polysaccharides. Typhoid conjugate vaccine is recommended by the World Health Organization since it may be more effective and prevent typhoid fever in many children under the age of five.
Which Vaccine Largely aids towards the Growth of the Global Paediatric Vaccine Market?
Monovalent vaccines hold the highest market share of around 74.4% during the year 2021, with an expected growth at a CAGR of 11.2% by the end of the forecast period.
The adoption of monovalent vaccines is more as compared to multivalent vaccines. A monovalent vaccine is made to immunize against a single antigen or one particular pathogen. Monovalent vaccines like MUMPSVAX, ATTENUVAX and MERUVAX, are administered for disease like measles, mumps and rubella respectively.
Which End User Benefits the Most with the Sales of Paediatric Vaccine Globally?
Institutional health centers hold the highest market share of 72.3% during the year 2021. In these facilities, qualified healthcare personnel are conveniently accessible. This segment will continue to have the largest market share due to the availability of all vaccines on a single platform in such institutional health centres and the access to various government programmes.
Competitive landscape
The market for the production of paediatric vaccine is fragmented, with several competitors. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new product releases to satisfy consumer demand and increase their client base.
- On 31 August 2022, Pfizer Inc and BioNTech SE announced the U.S. FDA immediate use of a booster dose of the Pfizer-BioNTech COVID-19 vaccine for people 12 years of age and older.
- In June 2022, GlaaxoSmithKline Plc., declared that the US Food and Drug Administration (FDA) has authorized Priorix for active immunization for the prevention of mumps, measles, and rubella in people 12 months of age and older.
Similarly, recent developments related to companies manufacturing paediatric vaccines, have been tracked by the team at Future Market Insights, which are available in the full report.
Report Scope As Per Paediatric Vaccine Industry Analysis
|
Attribute |
Details |
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2014-2022 |
|
Market Analysis |
US$ Mn for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
|
Key Countries Covered |
U.S., Canada Brazil, Mexico, Argentina, U.K., Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, North Africa |
|
Key Market Segments Covered |
Indication, Technology, Vaccine, End User and Region |
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered In Paediatric Vaccine Industry Research
By Indication:
- Pneumococcal Conjugate Vaccine
- DTP Vaccine
- Influenza
- Meningococcal Vaccine
- Polio Vaccine
- Rotavirus Vaccine
- MMR Vaccine
- Varicella Virus Vaccine
By Technology:
- Live or Attenuated Vaccine
- Inactivated or Killed Vaccine
- Toxoid Vaccine
- Conjugate Vaccine
- Subunit Vaccine
- Recombinant Vector Vaccine
By Vaccine:
- Monovalent Vaccines
- Multivalent Vaccines
By End User:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Health Centers
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
The global paediatric vaccine market is worth US$ 44.2 Bn in 2021 and is set to expand 3.3X over the next ten years.
New vaccine launches, rising diseases like typhoid, pneumonia and rubella among children, and awareness among people, are some of the key trends in this market.
GlaaxoSmithKline Plc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech and Indian Immnunologicals, and Catalent Inc are some of the key players in paediatric vaccine industry.
China accounts for about 5.6% of market share in 2021 in the global market.
The U.S., China, India, Canada and U.K. are expected to drive demand for the paediatric vaccine industry.
North America is one of the key markets for paediatric vaccine, with the U.S. accounting for about 72.7% of the North American paediatric vaccine market in the year 2021.
Paediatric vaccine is mostly produced in the U.S, and Canada.
From 2014-2021, the market for paediatric vaccine expanded at the rate of 9.4%.
India accounts for about 23.6% of market share in 2021 in the South Asian market and is projected to grow with a CAGR of 18.3% in the forecast period.
Demand for paediatric vaccine in Japan is expected to register a growth of 6.3% over the next ten years.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/ Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development/Innovation Trends
4. Key Success Factors
4.1. Technology Roadmap
4.2. PESTEL Analysis
4.3. Porter’s Analysis
4.4. Indication Features/ USPs
4.5. Key Promotional Strategies, By Key Manufacturers
4.6. Regulatory Landscape
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.1.3. Global Vaccines Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Key Player’s Historic Growth
5.2.2. Growing Prevalence of Chronic and Infectious Diseases
5.2.3. Rise in Government and Non-Government Funding for the Development of Novel Vaccines
5.2.4. New Product Launches / Approvals
5.2.5. Growing Initiatives for Immunization Awareness
5.2.6. Rising Approvals for Drugs and Biologics
5.2.7. Impact of Availability of Biosimilar
5.2.8. Technological Advancements
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis – Impact Assessment
6.1. COVID-19 and Impact Analysis
6.1.1. By Indication
6.1.2. By Technology
6.1.3. By Vaccine
6.1.4. By End User
6.1.5. By Region
6.2. 2021 Market Scenario
7. Global Paediatric Vaccine Market Demand Value or Size (US$ Mn) Analysis 2014 – 2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2014 – 2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Paediatric Vaccine Market Analysis 2014– 2021 and Forecast 2022–2032, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By indication, 2014 – 2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022–2032
8.3.1. Pneumococcal Conjugate Vaccine
8.3.2. DTP Vaccine
8.3.3. Influenza
8.3.4. Meningococcal Vaccine
8.3.5. Polio Vaccine
8.3.6. Rotavirus Vaccine
8.3.7. MMR Vaccine
8.3.8. Varicella Virus Vaccine
8.4. Market Attractiveness Analysis By Indication
9. Global Paediatric Vaccine Market Analysis 2014– 2021 and Forecast 2022–2032, By Technology
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) By Technology, 2014 – 2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Technology, 2022–2032
9.3.1. Live or Attenuated Vaccine
9.3.2. Inactivated or Killed Vaccine
9.3.3. Toxoid Vaccine
9.3.4. Conjugate Vaccine
9.3.5. Subunit Vaccine
9.3.6. Recombinant Vector Vaccine
9.4. Market Attractiveness Analysis By Indication
10. Global Paediatric Vaccine Market Analysis 2014– 2021 and Forecast 2022–2032, By Vaccine
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) By Vaccine, 2014 – 2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Vaccine, 2022–2032
10.3.1. Monovalent Vaccines
10.3.2. Multivalent Vaccines
10.4. Market Attractiveness Analysis By Vaccine
11. Global Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) By End User, 2014 – 2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022–2032
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Institutional Health Centers
11.4. Market Attractiveness Analysis By End User
12. Global Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2014 – 2021
12.3. Current Market Size (US$ Mn) and Forecast by Region, 2022–2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Indication
13.3.3. By Technology
13.3.4. By Vaccine
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Indication
13.4.3. By Technology
13.4.4. By Vaccine
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Paediatric Vaccine Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Indication
13.8.1.2.2. By Technology
13.8.1.2.3. By Vaccine
13.8.1.2.4. By End User
13.8.2. Canada Paediatric Vaccine Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Indication
13.8.2.2.2. By Technology
13.8.2.2.3. By Vaccine
13.8.2.2.4. By End User
14. Latin America Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Indication
14.3.3. By Technology
14.3.4. By Vaccine
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Indication
14.4.3. By Technology
14.4.4. By Vaccine
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Paediatric Vaccine Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Indication
14.8.1.2.2. By Technology
14.8.1.2.3. By Vaccine
14.8.1.2.4. By End User
14.8.2. Brazil Paediatric Vaccine Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Indication
14.8.2.2.2. By Technology
14.8.2.2.3. By Vaccine
14.8.2.2.4. By End User
14.8.3. Argentina Paediatric Vaccine Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Indication
14.8.3.2.2. By Technology
14.8.3.2.3. By Vaccine
14.8.3.2.4. By End User
15. Europe Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021
15.3. Current and Future Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Indication
15.3.3. By Technology
15.3.4. By Vaccine
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Indication
15.4.3. By Technology
15.4.4. By Vaccine
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Paediatric Vaccine Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Indication
15.8.1.2.2. By Technology
15.8.1.2.3. By Vaccine
15.8.1.2.4. By End User
15.8.2. Italy Paediatric Vaccine Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Indication
15.8.2.2.2. By Technology
15.8.2.2.3. By Vaccine
15.8.2.2.4. By End User
15.8.3. France Paediatric Vaccine Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Indication
15.8.3.2.2. By Technology
15.8.3.2.3. By Vaccine
15.8.3.2.4. By End User
15.8.4. U.K. Paediatric Vaccine Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Indication
15.8.4.2.2. By Technology
15.8.4.2.3. By Vaccine
15.8.4.2.4. By End User
15.8.5. Spain Paediatric Vaccine Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Indication
15.8.5.2.2. By Technology
15.8.5.2.3. By Vaccine
15.8.5.2.4. By End User
15.8.6. BENELUX Paediatric Vaccine Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Indication
15.8.6.2.2. By Technology
15.8.6.2.3. By Vaccine
15.8.6.2.4. By End User
15.8.7. Russia Paediatric Vaccine Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Indication
15.8.7.2.2. By Technology
15.8.7.2.3. By Vaccine
15.8.7.2.4. By End User
16. East Asia Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021
16.3. Current and Future Market Size (US$ Mn and Forecast by Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Indication
16.3.3. By Technology
16.3.4. By Vaccine
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Indication
16.4.3. By Indication
16.4.4. By Vaccine
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Paediatric Vaccine Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Indication
16.8.1.2.2. By Technology
16.8.1.2.3. By Vaccine
16.8.1.2.4. By End User
16.8.2. Japan Paediatric Vaccine Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Indication
16.8.2.2.2. By Technology
16.8.2.2.3. By Vaccine
16.8.2.2.4. By End User
16.8.3. South Korea Paediatric Vaccine Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Indication
16.8.3.2.2. By Technology
16.8.3.2.3. By Vaccine
16.8.3.2.4. By End User
17. South Asia Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend by Market Taxonomy, 2014 – 2021
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Indication
17.3.3. By Technology
17.3.4. By Vaccine
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Indication
17.4.3. By Technology
17.4.4. By Vaccine
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. India Paediatric Vaccine Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Indication
17.8.1.2.2. By Technology
17.8.1.2.3. By Vaccine
17.8.1.2.4. By End User
17.8.2. Indonesia Paediatric Vaccine Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Indication
17.8.2.2.2. By Technology
17.8.2.2.3. By Vaccine
17.8.2.2.4. By End User
17.8.3. Malaysia Paediatric Vaccine Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Indication
17.8.3.2.2. By Technology
17.8.3.2.3. By Vaccine
17.8.3.2.4. By End User
17.8.4. Thailand Paediatric Vaccine Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Indication
17.8.4.2.2. By Technology
17.8.4.2.3. By Vaccine
17.8.4.2.4. By End User
18. Oceania Paediatric Vaccine Market 2014-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Indication
18.3.3. By Technology
18.3.4. By Vaccine
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Indication
18.4.3. By Technology
18.4.4. By Vaccine
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Paediatric Vaccine Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Indication
18.8.1.2.2. By Technology
18.8.1.2.3. By Vaccine
18.8.1.2.4. By End User
18.8.2. New Zealand Paediatric Vaccine Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Indication
18.8.2.2.2. By Technology
18.8.2.2.3. By Vaccine
18.8.2.2.4. By End User
19. Middle East and Africa (MEA) Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021
19.3. Current and Future Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022–2032
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Indication
19.3.3. By Indication
19.3.4. By Vaccine
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Indication
19.4.3. By Technology
19.4.4. By Vaccine
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Paediatric Vaccine Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Indication
19.8.1.2.2. By Technology
19.8.1.2.3. By Vaccine
19.8.1.2.4. By End User
19.8.2. Turkey Paediatric Vaccine Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Indication
19.8.2.2.2. By Technology
19.8.2.2.3. By Vaccine
19.8.2.2.4. By End User
19.8.3. South Africa Paediatric Vaccine Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Indication
19.8.3.2.2. By Technology
19.8.3.2.3. By Vaccine
19.8.3.2.4. By End User
19.8.4. North Africa Paediatric Vaccine Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Indication
19.8.4.2.2. By Technology
19.8.4.2.3. By Vaccine
19.8.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players (%)
20.3. Market Presence Analysis
20.3.1. By Regional Footprint of Players
20.3.2. Indication Footprint of Players
20.3.3. Channel Footprint of Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. GlaxoSmithKline Plc.
21.3.1.1. Overview
21.3.1.2. Indication & Services Portfolio
21.3.1.3. Key Financials
21.3.1.4. SWOT Analysis
21.3.1.5. Key Developments
21.3.1.6. Sales Footprint
21.3.1.7. Strategy Overview
21.3.1.7.1. Marketing Strategy
21.3.1.7.2. Indication Strategy
21.3.1.7.3. Channel Strategy
21.3.2. Merck & Co. Inc
21.3.2.1. Overview
21.3.2.2. Indication & Services Portfolio
21.3.2.3. Key Financials
21.3.2.4. SWOT Analysis
21.3.2.5. Key Developments
21.3.2.6. Sales Footprint
21.3.2.7. Strategy Overview
21.3.2.7.1. Marketing Strategy
21.3.2.7.2. Indication Strategy
21.3.2.7.3. Channel Strategy
21.3.3. Pfizer Inc.
21.3.3.1. Overview
21.3.3.2. Indication & Services Portfolio
21.3.3.3. Key Financials
21.3.3.4. SWOT Analysis
21.3.3.5. Key Developments
21.3.3.6. Sales Footprint
21.3.3.7. Strategy Overview
21.3.3.7.1. Marketing Strategy
21.3.3.7.2. Indication Strategy
21.3.3.7.3. Channel Strategy
21.3.4. Sanofi SA
21.3.4.1. Overview
21.3.4.2. Indication & Services Portfolio
21.3.4.3. Key Financials
21.3.4.4. SWOT Analysis
21.3.4.5. Key Developments
21.3.4.6. Sales Footprint
21.3.4.7. Strategy Overview
21.3.4.7.1. Marketing Strategy
21.3.4.7.2. Indication Strategy
21.3.4.7.3. Channel Strategy
21.3.5. Panacea Biotec
21.3.5.1. Overview
21.3.5.2. Indication & Services Portfolio
21.3.5.3. Key Financials
21.3.5.4. SWOT Analysis
21.3.5.5. Key Developments
21.3.5.6. Sales Footprint
21.3.5.7. Strategy Overview
21.3.5.7.1. Marketing Strategy
21.3.5.7.2. Indication Strategy
21.3.5.7.3. Channel Strategy
21.3.6. Zydus Cadila
21.3.6.1. Overview
21.3.6.2. Indication & Services Portfolio
21.3.6.3. Key Financials
21.3.6.4. SWOT Analysis
21.3.6.5. Key Developments
21.3.6.6. Sales Footprint
21.3.6.7. Strategy Overview
21.3.6.7.1. Marketing Strategy
21.3.6.7.2. Indication Strategy
21.3.6.7.3. Channel Strategy
21.3.7. Emergent BioSolutions Inc
21.3.7.1. Overview
21.3.7.2. Indication & Services Portfolio
21.3.7.3. Key Financials
21.3.7.4. SWOT Analysis
21.3.7.5. Key Developments
21.3.7.6. Sales Footprint
21.3.7.7. Strategy Overview
21.3.7.7.1. Marketing Strategy
21.3.7.7.2. Indication Strategy
21.3.7.7.3. Channel Strategy
21.3.8. Serum Institute of India Pvt. Ltd.
21.3.8.1. Overview
21.3.8.2. Indication & Services Portfolio
21.3.8.3. Key Financials
21.3.8.4. SWOT Analysis
21.3.8.5. Key Developments
21.3.8.6. Sales Footprint
21.3.8.7. Strategy Overview
21.3.8.7.1. Marketing Strategy
21.3.8.7.2. Indication Strategy
21.3.8.7.3. Channel Strategy
21.3.9. Bharat Biotech and Indian Immnunologicals
21.3.9.1. Overview
21.3.9.2. Indication & Services Portfolio
21.3.9.3. Key Financials
21.3.9.4. SWOT Analysis
21.3.9.5. Key Developments
21.3.9.6. Sales Footprint
21.3.9.7. Strategy Overview
21.3.9.7.1. Marketing Strategy
21.3.9.7.2. Indication Strategy
21.3.9.7.3. Channel Strategy
21.3.10. Catalent Inc
21.3.10.1. Overview
21.3.10.2. Indication & Services Portfolio
21.3.10.3. Key Financials
21.3.10.4. SWOT Analysis
21.3.10.5. Key Developments
21.3.10.6. Sales Footprint
21.3.10.7. Strategy Overview
21.3.10.7.1. Marketing Strategy
21.3.10.7.2. Indication Strategy
21.3.10.7.3. Channel Strategy
21.3.11. Robinson Pharma, Inc.
21.3.11.1. Overview
21.3.11.2. Indication & Services Portfolio
21.3.11.3. Key Financials
21.3.11.4. SWOT Analysis
21.3.11.5. Key Developments
21.3.11.6. Sales Footprint
21.3.11.7. Strategy Overview
21.3.11.7.1. Marketing Strategy
21.3.11.7.2. Indication Strategy
21.3.11.7.3. Channel Strategy
21.3.12. Hunan Er-Kang Pharmaceutical Co., Ltd.
21.3.12.1. Overview
21.3.12.2. Indication & Services Portfolio
21.3.12.3. Key Financials
21.3.12.4. SWOT Analysis
21.3.12.5. Key Developments
21.3.12.6. Sales Footprint
21.3.12.7. Strategy Overview
21.3.12.7.1. Marketing Strategy
21.3.12.7.2. Indication Strategy
21.3.12.7.3. Channel Strategy
21.3.13. Procaps
21.3.13.1. Overview
21.3.13.2. Indication & Services Portfolio
21.3.13.3. Key Financials
21.3.13.4. SWOT Analysis
21.3.13.5. Key Developments
21.3.13.6. Sales Footprint
21.3.13.7. Strategy Overview
21.3.13.7.1. Marketing Strategy
21.3.13.7.2. Indication Strategy
21.3.13.7.3. Channel Strategy
21.3.14. CAPTEK Softgel International Inc.
21.3.14.1. Overview
21.3.14.2. Indication & Services Portfolio
21.3.14.3. Key Financials
21.3.14.4. SWOT Analysis
21.3.14.5. Key Developments
21.3.14.6. Sales Footprint
21.3.14.7. Strategy Overview
21.3.14.7.1. Marketing Strategy
21.3.14.7.2. Indication Strategy
21.3.14.7.3. Channel Strategy
21.3.15. Softcaps, Fuji Capsule Co., Ltd.
21.3.15.1. Overview
21.3.15.2. Indication & Services Portfolio
21.3.15.3. Key Financials
21.3.15.4. SWOT Analysis
21.3.15.5. Key Developments
21.3.15.6. Sales Footprint
21.3.15.7. Strategy Overview
21.3.15.7.1. Marketing Strategy
21.3.15.7.2. Indication Strategy
21.3.15.7.3. Channel Strategy
21.3.16. Aenova Holding GmbH
21.3.16.1. Overview
21.3.16.2. Indication & Services Portfolio
21.3.16.3. Key Financials
21.3.16.4. SWOT Analysis
21.3.16.5. Key Developments
21.3.16.6. Sales Footprint
21.3.16.7. Strategy Overview
21.3.16.7.1. Marketing Strategy
21.3.16.7.2. Indication Strategy
21.3.16.7.3. Channel Strategy
21.3.17. Sirio Pharma Co., Ltd.
21.3.17.1. Overview
21.3.17.2. Indication & Services Portfolio
21.3.17.3. Key Financials
21.3.17.4. SWOT Analysis
21.3.17.5. Key Developments
21.3.17.6. Sales Footprint
21.3.17.7. Strategy Overview
21.3.17.7.1. Marketing Strategy
21.3.17.7.2. Indication Strategy
21.3.17.7.3. Channel Strategy
21.3.18. Bahrain Pharma
21.3.18.1. Overview
21.3.18.2. Indication & Services Portfolio
21.3.18.3. Key Financials
21.3.18.4. SWOT Analysis
21.3.18.5. Key Developments
21.3.18.6. Sales Footprint
21.3.18.7. Strategy Overview
21.3.18.7.1. Marketing Strategy
21.3.18.7.2. Indication Strategy
21.3.18.7.3. Channel Strategy
21.3.19. Sinovac Biotech Ltd.
21.3.19.1. Overview
21.3.19.2. Indication & Services Portfolio
21.3.19.3. Key Financials
21.3.19.4. SWOT Analysis
21.3.19.5. Key Developments
21.3.19.6. Sales Footprint
21.3.19.7. Strategy Overview
21.3.19.7.1. Marketing Strategy
21.3.19.7.2. Indication Strategy
21.3.19.7.3. Channel Strategy
21.3.20. AstraZeneca plc
21.3.20.1. Overview
21.3.20.2. Indication & Services Portfolio
21.3.20.3. Key Financials
21.3.20.4. SWOT Analysis
21.3.20.5. Key Developments
21.3.20.6. Sales Footprint
21.3.20.7. Strategy Overview
21.3.20.7.1. Marketing Strategy
21.3.20.7.2. Indication Strategy
21.3.20.7.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Indication
Table 02: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Technology
Table 03: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Vaccine
Table 04: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by End User
Table 05: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Region
Table 06: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country
Table 07: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication
Table 08: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Technology
Table 09: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Vaccine
Table 10: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by End User
Table 11: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country
Table 12: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication
Table 13: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Technology
Table 14: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Vaccine
Table 15: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by End User
Table 16: Europe Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country
Table 17: Europe Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication
Table 18: Europe Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Technology
Table 19: Europe Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Vaccine
Table 20: Europe Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by End User
Table 21: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country
Table 22: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication
Table 23: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Technology
Table 24: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Vaccine
Table 25: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by End User
Table 26: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country
Table 27: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication
Table 28: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Technology
Table 29: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Vaccine
Table 30: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by End User
Table 31: Oceania Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country
Table 32: Oceania Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication
Table 33: Oceania Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Technology
Table 34: Oceania Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Vaccine
Table 35: Oceania Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by End User
Table 36: Middle East & Africa Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country
Table 37: Middle East & Africa Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication
Table 38: Middle East & Africa Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Technology
Table 39: Middle East & Africa Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Vaccine
Table 40: Middle East & Africa Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021
Figure 02: Global Paediatric Vaccines Market Forecast & Y-o-Y Growth, 2022–2032
Figure 03: Global Paediatric Vaccines Market Absolute $ Opportunity (US$ Mn) Analysis, 2021–2032
Figure 04: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by Indication
Figure 05: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by Indication
Figure 06: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by Indication
Figure 07: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by Technology
Figure 08: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by Technology
Figure 09: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by Technology
Figure 10: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by Vaccine
Figure 11: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by Vaccine
Figure 12: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by Vaccine
Figure 13: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by End User
Figure 14: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by End User
Figure 15: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by End User
Figure 16: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by Region
Figure 17: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by Region
Figure 18: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by Region
Figure 19: North America Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021
Figure 20: North America Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032
Figure 21: North America Paediatric Vaccines Market Value Share, by Indication (2022 E)
Figure 22: North America Paediatric Vaccines Market Value Share, by Technology (2022 E)
Figure 23: North America Paediatric Vaccines Market Value Share, by Vaccine (2022 E)
Figure 24: North America Paediatric Vaccines Market Value Share, by End User (2022 E)
Figure 25: North America Paediatric Vaccines Market Value Share, by Country (2022 E)
Figure 26: North America Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032
Figure 27: North America Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032
Figure 28: North America Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032
Figure 29: North America Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032
Figure 30: North America Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032
Figure 31: U.S. Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 32: Global Vs. U.S. Growth Comparison
Figure 33: U.S. Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 34: U.S. Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 35: U.S. Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 36: U.S. Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 37: Canada Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 38: Global Vs. Canada. Growth Comparison
Figure 39: Canada Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 40: Canada Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 41: Canada Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 42: Canada Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 43: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021
Figure 44: Latin America Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032
Figure 45: Latin America Paediatric Vaccines Market Value Share, by Indication (2022 E)
Figure 46: Latin America Paediatric Vaccines Market Value Share, by Technology (2022 E)
Figure 47: Latin America Paediatric Vaccines Market Value Share, by Vaccine (2022 E)
Figure 48: Latin America Paediatric Vaccines Market Value Share, by End User (2022 E)
Figure 49: Latin America Paediatric Vaccines Market Value Share, by Country (2022 E)
Figure 50: Latin America Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032
Figure 51: Latin America Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032
Figure 52: Latin America Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032
Figure 53: Latin America Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032
Figure 54: Latin America Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032
Figure 55: Mexico Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 56: Global Vs Mexico Growth Comparison
Figure 57: Mexico Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 58: Mexico Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 59: Mexico Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 60: Mexico Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 61: Brazil Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 62: Global Vs. Brazil. Growth Comparison
Figure 63: Brazil Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 64: Brazil Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 65: Brazil Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 66: Brazil Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 67: Argentina Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 68: Global Vs Argentina Growth Comparison
Figure 69: Argentina Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 70: Argentina Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 71: Argentina Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 72: Argentina Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 73: Europe Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021
Figure 74: Europe Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032
Figure 75: Europe Paediatric Vaccines Market Value Share, by Indication (2022 E)
Figure 76: Europe Paediatric Vaccines Market Value Share, by Technology (2022 E)
Figure 77: Europe Paediatric Vaccines Market Value Share, by Vaccine (2022 E)
Figure 78: Europe Paediatric Vaccines Market Value Share, by End User (2022 E)
Figure 79: Europe Paediatric Vaccines Market Value Share, by Country (2022 E)
Figure 80: Europe Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032
Figure 81: Europe Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032
Figure 82: Europe Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032
Figure 83: Europe Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032
Figure 84: Europe Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032
Figure 85: UK Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 86: Global Vs. UK Growth Comparison
Figure 87: UK Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 88: UK Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 89: UK Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 90: UK Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 91: Germany Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 92: Global Vs. Germany Growth Comparison
Figure 93: Germany Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 94: Germany Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 95: Germany Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 96: Germany Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 97: Italy Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 98: Global Vs. Italy Growth Comparison
Figure 99: Italy Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 100: Italy Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 101: Italy Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 102: Italy Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 103: France Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 104: Global Vs France Growth Comparison
Figure 105: France Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 106: France Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 107: France Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 108: France Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 109: Spain Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 110: Global Vs Spain Growth Comparison
Figure 111: Spain Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 112: Spain Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 113: Spain Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 114: Spain Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 115: Russia Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 116: Global Vs Russia Growth Comparison
Figure 117: Russia Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 118: Russia Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 119: Russia Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 120: Russia Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 121: BENELUX Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 122: Global Vs BENELUX Growth Comparison
Figure 123: BENELUX Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 124: BENELUX Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 125: BENELUX Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 126: BENELUX Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 127: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021
Figure 128: East Asia Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032
Figure 129: East Asia Paediatric Vaccines Market Value Share, by Indication (2022 E)
Figure 130: East Asia Paediatric Vaccines Market Value Share, by Technology (2022 E)
Figure 131: East Asia Paediatric Vaccines Market Value Share, by Vaccine (2022 E)
Figure 132: East Asia Paediatric Vaccines Market Value Share, by End User (2022 E)
Figure 133: East Asia Paediatric Vaccines Market Value Share, by Country (2022 E)
Figure 134: East Asia Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032
Figure 135: East Asia Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032
Figure 136: East Asia Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032
Figure 137: East Asia Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032
Figure 138: East Asia Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032
Figure 139: China Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 140: Global Vs. China Growth Comparison
Figure 141: China Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 142: China Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 143: China Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 144: China Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 145: Japan Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 146: Global Vs. Japan Growth Comparison
Figure 147: Japan Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 148: Japan Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 149: Japan Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 150: Japan Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 151: South Korea Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 152: Global Vs South Korea Growth Comparison
Figure 153: South Korea Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 154: South Korea Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 155: South Korea Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 156: South Korea Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 157: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021
Figure 158: South Asia Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032
Figure 159: South Asia Paediatric Vaccines Market Value Share, by Indication (2022 E)
Figure 160: South Asia Paediatric Vaccines Market Value Share, by Technology (2022 E)
Figure 161: South Asia Paediatric Vaccines Market Value Share, by Vaccine (2022 E)
Figure 162: South Asia Paediatric Vaccines Market Value Share, by End User (2022 E)
Figure 163: South Asia Paediatric Vaccines Market Value Share, by Country (2022 E)
Figure 164: South Asia Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032
Figure 165: South Asia Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032
Figure 166: South Asia Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032
Figure 167: South Asia Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032
Figure 168: South Asia Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032
Figure 169: India Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 170: Global Vs. India Growth Comparison
Figure 171: India Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 172: India Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 173: India Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 174: India Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 175: Indonesia Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 176: Global Vs. Indonesia Growth Comparison
Figure 177: Indonesia Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 178: Indonesia Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 179: Indonesia Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 180: Indonesia Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 181: Malaysia Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 182: Global Vs. Malaysia Growth Comparison
Figure 183: Malaysia Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 184: Malaysia Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 185: Malaysia Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 186: Malaysia Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 187: Thailand Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 188: Global Vs. Thailand Growth Comparison
Figure 189: Thailand Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 190: Thailand Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 191: Thailand Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 192: Thailand Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 193: Oceania Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021
Figure 194: Oceania Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032
Figure 195: Oceania Paediatric Vaccines Market Value Share, by Indication (2022 E)
Figure 196: Oceania Paediatric Vaccines Market Value Share, by Technology (2022 E)
Figure 197: Oceania Paediatric Vaccines Market Value Share, by Vaccine (2022 E)
Figure 198: Oceania Paediatric Vaccines Market Value Share, by End User (2022 E)
Figure 199: Oceania Paediatric Vaccines Market Value Share, by Country (2022 E)
Figure 200: Oceania Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032
Figure 201: Oceania Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032
Figure 202: Oceania Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032
Figure 203: Oceania Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032
Figure 204: Oceania Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032
Figure 205: Australia Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 206: Global Vs. Australia Growth Comparison
Figure 207: Australia Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 208: Australia Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 209: Australia Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 210: Australia Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 211: New Zealand Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 212: Global Vs New Zealand Growth Comparison
Figure 213: New Zealand Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 214: New Zealand Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 215: New Zealand Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 216: New Zealand Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 217: Middle East & Africa Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021
Figure 218: Middle East & Africa Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032
Figure 219: Middle East & Africa Paediatric Vaccines Market Value Share, by Indication (2022 E)
Figure 220: Middle East & Africa Paediatric Vaccines Market Value Share, by Technology (2022 E)
Figure 221: Middle East & Africa Paediatric Vaccines Market Value Share, by Vaccine (2022 E)
Figure 222: Middle East & Africa Paediatric Vaccines Market Value Share, by End User (2022 E)
Figure 223: Middle East & Africa Paediatric Vaccines Market Value Share, by Country (2022 E)
Figure 224: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032
Figure 225: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032
Figure 226: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032
Figure 227: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032
Figure 228: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032
Figure 229: GCC Countries Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 230: Global Vs GCC Countries Growth Comparison
Figure 231: GCC Countries Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 232: GCC Countries Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 233: GCC Countries Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 234: GCC Countries Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 235: Turkey Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 236: Global Vs. Turkey Growth Comparison
Figure 237: Turkey Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 238: Turkey Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 239: Turkey Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 240: Turkey Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 241: South Africa Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 242: Global Vs. South Africa Growth Comparison
Figure 243: South Africa Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 244: South Africa Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 245: South Africa Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 246: South Africa Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Figure 247: North Africa Paediatric Vaccines Market Value Proportion Analysis, 2021
Figure 248: Global Vs North Africa Growth Comparison
Figure 249: North Africa Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032
Figure 250: North Africa Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032
Figure 251: North Africa Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032
Figure 252: North Africa Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
